OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
Ematobase.it
Onco News

Search results for "Keytruda"

The U.S. Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and ...


Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced gastric cancer were presented during the ESMO ( European Society for Medical Oncology ) 2 ...


Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced urothelial cancer ( also known as bladder cancer ) presented at ESMO ( European Society f ...


The anti-programmed-death-receptor-1 ( PD-1 ) antibody Pembrolizumab ( Keytruda ) has shown potent antitumour activity at different doses and schedules in patients with melanoma. Researchers have co ...


Findings investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer ( SCLC ), esophageal cancer and o ...


Pembrolizumab ( Keytruda ), an anti–PD-1 antibody, demonstrated antitumor activity and acceptable safety in patients with recurrent or metastatic PD-L1–positive urothelial cancer enrolled in the phase ...


New data from KEYNOTE-001, a phase 1b study evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in naïve and previously-treated patients with advanced non-small cell lung cancer ( NSCLC ) wer ...


Results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in p ...


Treatment with programmed death receptor-1 ( PD-1 ) antibodies is associated with high response rates in patients with advanced melanoma. Reliable markers for early response and outcome are still spar ...


The advent of new immunotherapies for the treatment of metastatic melanoma has resulted in various novel combination strategies. Because of their distinct modes of action, different immunotherapies ha ...


Epacadostat is an oral, potent, selective inhibitor of indoleamine 2,3-dioxygenase 1 ( IDO1 ), a tryptophan-catabolizing enzyme that induces immune tolerance by T-cell suppression. Preliminary phase ...


A treatment harnesses the immune system to shrink tumors in bladder cancer patients that cannot take the most effective chemotherapy. These are the findings of a clinical trial led by researchers at ...


Updated results from the phase 3 KEYNOTE-045 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial carcinoma with disease progre ...


Data from all three cohorts of the registrational, phase 2 KEYNOTE-059 trial investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in patients with advanced gastric or gastroesoph ...


Updated results from Cohort G of the phase 2 KEYNOTE-021 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Pemetrexed and Carboplatin ( Pem/Carbo ) in patients ...